U.S., Dec. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07298928) titled 'A Study on the Efficacy and Safety of Telitacicept in the Treatment of Children Ocular Myasthenia Gravis' on Dec. 09.
Brief Summary: Under conventional treatment regimens, pediatric ocular myasthenia gravis (OMG) is prone to relapse and is associated with corticosteroid-related adverse effects, indicating an unmet clinical need. In May 2025, the targeted B-cell biologic agent Telitacicept was approved for use in adult patients with acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (GMG) and subsequently initiated in national multicenter clinical trials for adult OMG. Our center published a retrospective s...